M D'Hondt1, F Nuytens2, L Kinget3, M Decaestecker3, B Borgers4, I Parmentier5. 1. Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, President Kennedylaan 4, 8500, Kortrijk, Belgium. mathieudhondt2000@yahoo.com. 2. Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, President Kennedylaan 4, 8500, Kortrijk, Belgium. 3. Faculty of Medicine, KU Leuven, Leuven, Belgium. 4. Faculty of Medicine and Health Sciences, UGent, De Pintelaan 135, 9000, Ghent, Belgium. 5. Department of Oncology and Statistics, Groeninge Hospital, President Kennedylaan 4, 8500, Kortrijk, Belgium.
Abstract
PURPOSE: Sacral neurostimulation (SNS) has proven to be an effective treatment modality for low anterior resection syndrome (LARS). The primary aim of this study is to investigate the impact of SNS on all symptoms of LARS, not merely on fecal incontinence. Furthermore, we wanted to evaluate whether the LARS score could be useful as a tool to evaluate SNS treatment. METHODS: All patients diagnosed with minor or major LARS, unresponsive to conservative therapy for fecal incontinence, who underwent sacral neuromodulation for LARS at Groeninge Hospital, Kortrijk, Belgium, were prospectively enrolled in the study. The primary endpoint was the reduction in the severity of LARS. This was assessed by validated questionnaires: the LARS score and the Wexner score. RESULTS: Eleven patients underwent definite implantation of the SNS device. All patients showed a substantial decrease in their Wexner scores: The mean score was reduced from 17.7 to 4.6 (Z: 2.93; p: 0.0033). Additionally, the mean LARS score dropped from 36.9 to 11.4 (Z: 2.93; p: 0.0033). Furthermore, there was a significant amelioration of all symptoms of LARS. CONCLUSIONS: Our study shows that SNS is effective for all symptoms of LARS. The authors believe that in patients who receive SNS for LARS, it could be useful to determine the LARS score to evaluate the complexity of the symptoms and their response to treatment.
PURPOSE: Sacral neurostimulation (SNS) has proven to be an effective treatment modality for low anterior resection syndrome (LARS). The primary aim of this study is to investigate the impact of SNS on all symptoms of LARS, not merely on fecal incontinence. Furthermore, we wanted to evaluate whether the LARS score could be useful as a tool to evaluate SNS treatment. METHODS: All patients diagnosed with minor or major LARS, unresponsive to conservative therapy for fecal incontinence, who underwent sacral neuromodulation for LARS at Groeninge Hospital, Kortrijk, Belgium, were prospectively enrolled in the study. The primary endpoint was the reduction in the severity of LARS. This was assessed by validated questionnaires: the LARS score and the Wexner score. RESULTS: Eleven patients underwent definite implantation of the SNS device. All patients showed a substantial decrease in their Wexner scores: The mean score was reduced from 17.7 to 4.6 (Z: 2.93; p: 0.0033). Additionally, the mean LARS score dropped from 36.9 to 11.4 (Z: 2.93; p: 0.0033). Furthermore, there was a significant amelioration of all symptoms of LARS. CONCLUSIONS: Our study shows that SNS is effective for all symptoms of LARS. The authors believe that in patients who receive SNS for LARS, it could be useful to determine the LARS score to evaluate the complexity of the symptoms and their response to treatment.
Authors: P Moya; A Arroyo; L Soriano-Irigaray; A Frangi; F Candela Polo; R Calpena Rico Journal: Tech Coloproctol Date: 2012-04-12 Impact factor: 3.781
Authors: Klaus E Matzel; Uwe Stadelmaier; Birgit Bittorf; M Hohenfellner; Werner Hohenberger Journal: Int J Colorectal Dis Date: 2002-07-03 Impact factor: 2.571
Authors: M Schiano di Visconte; G A Santoro; N Cracco; G Sarzo; G Bellio; M Brunner; Z Cui; K E Matzel Journal: Tech Coloproctol Date: 2018-01-08 Impact factor: 3.781
Authors: J Martellucci; A Sturiale; C Bergamini; L Boni; F Cianchi; A Coratti; A Valeri Journal: Tech Coloproctol Date: 2018-08-06 Impact factor: 3.781